Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bayer to Strengthen Women's Healthcare Field with Yaz
October 18, 2010
- Drug Categories Reviewed by 1st, 2nd Committees Changed
October 18, 2010
- No Dose Adjustment Required for Linagliptin in T2D Patients
October 18, 2010
- GSK to Strengthen CNS Franchise
October 18, 2010
- Korosho Creates 4 TFs to Stimulate Clinical Studies in Japan
October 18, 2010
- Hisamitsu: Acquisition of Noven Boosts Half-Year Sales
October 18, 2010
- Otsuka to Apply for Abilify IM Depot in the US in FY2011
October 18, 2010
- GSK Launches Paxil 5 mg Tablet
October 18, 2010
- Sucampo Pharma Applies for Amitiza in Japan
October 18, 2010
- DSP Launches Lonasen through Bukwang in South Korea
October 18, 2010
- Kapvay Approved for AD/HD in the US: Shionogi
October 18, 2010
- Otsuka Sets Up SalesSubsidiary in Canada
October 18, 2010
- Tasigna Recommended for EU Approval as 1st-Line Treatment for CML
October 18, 2010
- Zibotentan Fails to Extend OS in CRPC Patients
October 18, 2010
- SANTEC Transfers CRO Business to Clio Science
October 18, 2010
- Ticagrelor Receives Positive Opinion from CHMP
October 18, 2010
- Points Should Not Be Given for Out-of-Pocket Payments for Dispensing Services: JPA
October 18, 2010
- NHI Price Listing of Generic Aricept Remains Uncertain
October 18, 2010
- Korosho Revises Package Insert for Victoza Following Report of 2 Deaths
October 18, 2010
- Linagliptin Improves HbA1c with and without SU
October 18, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…